atai Life Sciences (NASDAQ: ATAI) has announced positive preliminary data from the first eight-patient arm of its Phase 2a trial showing the possibility of pro-cognitive effects of RL-007, a glutamatergic, cholinergic, and GABA type B receptor modulator for Cognitive Impairment Associated with Schizophrenia.
Findings allow for expedited clinical development for RL-007.
These preliminary findings have prompted atai to commit extra financial resources, allowing for an expedited clinical development timeframe for RL-007, even before the current Phase 2a trial is completed. The interim Phase 2a readout showed that two quantitative biomarkers, quantitative electroencephalogram, and evoked-response potential, showed positive results for the 8-patient sample, indicating alterations compatible with better cognition. With no viable treatments now available, CIAS is a major unmet need for persons living with Schizophrenia. By the end of 2021, the full results of the current Phase 2a trial should be available.
Recognify Life Science CEO and Co-founder Matthew Pando said, “With these data, from the interim analysis of the ongoing Phase 2a trial, we are encouraged to accelerate the overall development of RL-007 for CIAS. I would like to express my deepest gratitude to the patient volunteers who have supported our clinical trial thus far. I believe that, with continued support, we have the potential to bring benefit to patients living with Schizophrenia and its often very challenging cognitive impacts.”
Data supports trajectory for RF-007
atai Life Sciences CEO and Co-founder Florian Brand said, “We believe that, although preliminary, these promising data give us confidence to further support and expedite the clinical trajectory for RL-007 and we look forward to the full data set. With its unique mechanism of action, we think that RL-007 has potential to address a major unmet need in terms of addressing the cognitive deficits that can be so debilitating for people with Schizophrenia.”
CIAS is a major unmet need for Schizophrenia patients, and cognitive deficits are more common in patients with Schizophrenia.
